Liang-Ming Lee

Liang-Ming Lee

Auto-generated profile, based on publicly available information

Liang-Ming Lee

Department of Urology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2014 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
WLWei-Jiunn Lee
Wei-Jiunn Lee
Michael HsiaoMichael Hsiao
Michael Hsiao
JCJunn-Liang Chang
Junn-Liang Chang
SYShun-Fa Yang
Shun-Fa Yang
TTTsui-Hwa Tseng
Tsui-Hwa Tseng
MCMing-Hsien Chien
Ming-Hsien Chien

22 May 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
YWYu-Ching Wen
Yu-Ching Wen
WLWei-Jiunn Lee
Wei-Jiunn Lee
PTPeng Tan
Peng Tan
SYShun-Fa Yang
Shun-Fa Yang
Michael HsiaoMichael Hsiao
Michael Hsiao
MCMing-Hsien Chien
Ming-Hsien Chien
Here we showed that Osthole, 7-methoxy-8-(3-methyl-2-butenyl) coumarin, a bioactive coumarin derivative extracted from medicinal plants, inhibited migration, invasion, epithelial to mesenchymal transition (EMT) in androgen-independent prostate cancer (AIPC) cells in vitro and metastasis of AIPC in vivo. In patients, high Snail levels were correlated with a higher histological Gleason sum and poor survival rates. Osthole inhibited the TGF-β/Akt/MAPK pathways, reduced Snail-DNA-binding activity and induced E-cadherin. We found that osthole decreased miR-23a-3p. Ectopic miR-23a-3p suppressed E-cadherin 3’ untranslated region reporter activity and E-cadherin expression, and relieved the motility suppression caused by osthole treatment.

24 March 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JHJhy-Shrian Huang
Jhy-Shrian Huang
CYChih-Jung Yao
Chih-Jung Yao
SCShuang-En Chuang
Shuang-En Chuang
Chi-Tai YehChi-Tai Yeh
Chi-Tai Yeh
LLLiang-Ming Lee
Liang-Ming Lee
GLGi-Ming Lai
Gi-Ming Lai
Eliminating cancer stem cells (CSCs) has been suggested for prevention of tumor recurrence and metastasis. Honokiol, an active compound of Magnolia officinalis, had been proposed to be a potential candidate drug for cancer treatment. We explored its effects on the elimination of oral CSCs both in vitro and in vivo. By using the Hoechst side population (SP) technique, CSCs-like SP cells were isolated from human oral squamous cell carcinoma (OSCC) cell lines, SAS and OECM-1. Effects of honokiol on the apoptosis and signaling pathways of SP-derived spheres were examined by Annexin V/Propidium iodide staining and Western blotting, respectively. The in vivo effectiveness was examined by xenograft mouse model and immunohistochemical tissue staining. The SP cells possessed higher stemness marker expression (ABCG2, Ep-CAM, Oct-4 and Nestin), clonogenicity, sphere formation capacity as well as tumorigenicity when compared to the parental cells. Treatment of these SP-derived spheres with honokiol resulted in apoptosis induction via Bax/Bcl-2 and caspase-3-dependent pathway. This apoptosis induction was associated with marked suppression of JAK2/STAT3, Akt and Erk signaling pathways in honokiol-treated SAS spheres. Consistent with its effect on JAK2/STAT3 suppression, honokiol also markedly inhibited IL-6-mediated migration of SAS cells. Accordingly, honokiol dose-dependently inhibited the growth of SAS SP xenograft and markedly reduced the immunohistochemical staining of PCNA and endothelial marker CD31 in the xenograft tumor. Honokiol suppressed the sphere formation and xenograft growth of oral CSC-like cells in association with apoptosis induction and inhibition of survival/proliferation signaling pathways as well as angiogenesis. These results suggest its potential as an integrative medicine for combating oral cancer through targeting on CSCs.

21 August 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PHPei-Ching Hsiao
Pei-Ching Hsiao
YCYing-Erh Chou
Ying-Erh Chou
PTPeng Tan
Peng Tan
WLWei-Jiunn Lee
Wei-Jiunn Lee
SYShun-Fa Yang
Shun-Fa Yang
MCMing-Hsien Chien
Ming-Hsien Chien
Pterostilbene (PTER) is a dimethylated analog of the phenolic phytoalexin, resveratrol, with higher anticancer activity in various tumors. Herein, the molecular mechanisms by which PTER exerts its anticancer effects against acute myeloid leukemia (AML) cells were investigated. Results showed that PTER suppressed cell proliferation in various AML cell lines. PTER-induced G0/G1-phase arrest occurred when expressions of cyclin D3 and cyclin-dependent kinase (CDK)2/6 were inhibited. PTER-induced cell apoptosis occurred through activation of caspases-8-9/-3, and a mitochondrial membrane permeabilization (MMP)-dependent pathway. Moreover, treatment of HL-60 cells with PTER induced sustained activation of extracellular signal-regulated kinase (ERK)1/2 and c-Jun N-terminal kinase (JNK)1/2, and inhibition of both MAPKs by their specific inhibitors significantly abolished the PTER-induced activation of caspases-8/-9/-3. Of note, PTER-induced cell growth inhibition was only partially reversed by the caspase-3-specific inhibitor, Z-DEVE-FMK, suggesting that this compound may also act through a caspase-independent pathway. Interestingly, we also found that PTER promoted disruption of lysosomal membrane permeabilization (LMP) and release of activated cathepsin B. Taken together, our results suggest that PTER induced HL-60 cell death via MAPKs-mediated mitochondria apoptosis pathway and loss of LMP might be another cause for cell apoptosis induced by PTER.

15 March 2013 in Oncology Letters
Verified
Journal Article
Open access
PDF file
KYKun-Huang Yan
Kun-Huang Yan
YLYung-Wei Lin
Yung-Wei Lin
CHChi-Hao Hsiao
Chi-Hao Hsiao
YWYu-Ching Wen
Yu-Ching Wen
KLKe-Hsun Lin
Ke-Hsun Lin
LLLiang-Ming Lee
Liang-Ming Lee
Mefloquine (MQ) is currently in clinical use as a prophylactic treatment for malaria. Previous studies have shown that MQ induces oxidative stress in vitro. The present study investigated the anticancer effects of MQ treatment in PC3 cells. The cell viability was evaluated using sulphorhodamine-B (SRB) staining, while annexin V and propidium iodide (PI) were used as an assay for cell death. Reactive oxygen species (ROS) formation was detected with 2',7'‑dichlorofluorescein‑diacetate (DCFH‑DA), a sensitive intracellular probe, and the alteration of cellular status was defined by trypan blue staining. The results of the present study indicated that MQ has a high cytotoxicity that causes cell death in PC3 cells. MQ markedly inhibited the PC3 cells through non‑apoptotic cell death. MQ also induced significant ROS production. The MQ treatment mediated G1 cell cycle arrest and cyclin D1 accumulation through p21 upregulation in the PC3 cells. Moreover, the use of MQ improved the survival of the treatment group compared with the control group in the experimental mice. The present study indicates that MQ possesses potential therapeutic efficacy for the treatment of prostate cancer (PCa) in vivo. These findings provide insights that may aid the further optimization and application of new and existing therapeutic options.

22 February 2013 in Oncology Letters
Verified
Journal Article
Open access
PDF file
KYKun-Huang Yan
Kun-Huang Yan
CYChih-Jung Yao
Chih-Jung Yao
CHChi-Hao Hsiao
Chi-Hao Hsiao
KLKe-Hsun Lin
Ke-Hsun Lin
YLYung-Wei Lin
Yung-Wei Lin
LLLiang-Ming Lee
Liang-Ming Lee
Mefloquine (MQ) is a prophylactic anti-malarial drug. Previous studies have shown that MQ induces oxidative stress in vitro. Evidence indicates that reactive oxygen species (ROS) may be used as a therapeutic modality to kill cancer cells. This study investigated whether MQ also inhibits prostate cancer (PCa) cell growth. We used sulforhodamine B (SRB) staining to determine cell viability. MQ has a highly selective cytotoxicity that inhibits PCa cell growth. The antitumor effect was most significant when examined using a colony formation assay. MQ also induces hyperpolarization of the mitochondrial membrane potential (MMP), as well as ROS generation. The blockade of MQ-induced anticancer effects by N-acetyl cysteine (NAC) pre-treatment confirmed the role of ROS. This indicates that the MQ-induced anticancer effects are caused primarily by increased ROS generation. Moreover, we observed that MQ-mediated ROS simultaneously downregulated Akt phosphorylation and activated extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and adenosine monophosphate-activated protein kinase (AMPK) signaling in PC3 cells. These findings provide insights for further anticancer therapeutic options.